复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

未开盘 03-05 16:08:25

18.830

+0.380

+2.06%

最高19.080	最低18.650	成交量289.45万
今开18.970	昨收18.450	日振幅2.33%
总市值500.69亿	流通市值101.86亿	总股本26.59亿
成交额5,464万	换手率0.54%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":18.83,"timestamp":1772698105004,"preClose":18.45,"halted":0,"volume":2894500,"delay":0,"changeRate":0.020596205962059567,"floatShares":540971500,"shares":2659000000,"eps":1.037252,"marketStatus":"未开盘","change":0.38,"latestTime":"03-05 16:08:25","open":18.97,"high":19.08,"low":18.65,"amount":54640468,"amplitude":0.023306,"askPrice":18.83,"askSize":4000,"bidPrice":18.77,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":1.352842,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":18.45,"dividendRate":0.019277,"openAndCloseTimeList":[[1772674200000,1772683200000],[1772686800000,1772697600000]],"volumeRatio":0.9700131388726378,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":25.23,"timestamp":1772694000000,"preClose":25.01,"halted":0,"volume":11560200,"delay":0,"premium":"-34.01"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2617952592","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月5日股价上涨0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617952592","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617952592?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:30","pubTimestamp":1772721041,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，复星医药报收于25.23元，较前一交易日上涨0.88%，最新总市值为673.75亿元。近日，上海复星医药（集团）股份有限公司披露公告，其控股子公司复宏汉霖收到国家药品监督管理局批准，同意其自主研发的KAT6A/B小分子抑制剂HLX97开展用于晚期/转移性实体瘤治疗的Ⅰ期临床试验。该药品拟于条件具备后在中国境内开展临床研究。目前全球范围内尚无KAT6A/B小分子抑制剂获批上市。HLX97仍需经过临床研究及审评审批程序，存在研发风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500039568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK1191","BK0096","600196","BK0239","BK1515","BK1593","BK0060","02196","BK0196","BK0183","BK0012","BK0028","BK0188","BK0187"],"gpt_icon":0},{"id":"2617540395","title":"智通港股解盘 | 突发霍尔木兹海峡有限放开 关注明日人大记者招待会","url":"https://stock-news.laohu8.com/highlight/detail?id=2617540395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617540395?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:10","pubTimestamp":1772716245,"startTime":"0","endTime":"0","summary":"3 月 4 日，美国国会参议院对一项旨在限制总统战争权力的议案进行表决，该议案要求美国总统在进一步对伊朗采取军事行动前必须获得国会授权。然而下午发生突变：伊朗哈塔姆·安比亚中央司令部副司令阿米尔·海达里当地时间 5 日上午在接受采访时表示，伊朗方面并未封锁霍尔木兹海峡。其中年销售额超过 100 亿元的药品 40 余个。返程航班 CA790 计划于当地时间 3月 5 日 22:55 起飞，预计北京时间 3 月 6 日 12:52 飞抵北京。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287529.USD","LU1328277881.USD","BK1167","LU0326950275.SGD","LU2039709279.SGD","BK4588","BK1504","HK0000165453.HKD","LU0501845795.SGD","LU1226288253.USD","LU1993786604.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU0072913022.USD","IE0008368742.USD","LU0880133367.SGD","01093","IE00BZ08YR35.GBP","LU1226288170.HKD","BK1515","BK1191","BK1521","LU1960683339.HKD","VT","BK4585","LU1226287875.USD","LU0140636845.USD","LU1226287792.SGD","02038","LU1152091168.USD","BK1593","LU0067412154.USD","LU0315179316.USD","LU1008478684.HKD","IE00B543WZ88.USD","02196","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU1152091754.HKD","VXUS","SG9999004220.SGD","BK1508","LU1813983027.USD","LU0314109678.HKD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2617548081","title":"复星医药(600196.SH)：HLX97用于晚期/转移性实体瘤治疗获批准开展Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2617548081","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617548081?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:18","pubTimestamp":1772705892,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)收到国家药品监督管理局关于同意HLX97(即KAT6A/B小分子抑制剂)用于晚期/转移性实体瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后在中国境内1开展该药品的相关临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0060","BK0175","BK0183","BK0188","02196","BK0239","BK0196","BK0096","BK1593","BK0028","BK0187","600196","BK1515","BK1191"],"gpt_icon":0},{"id":"1169316832","title":"复星医药（02196）2026年2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1169316832","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169316832?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:26","pubTimestamp":1772699175,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年3月5日披露2026年2月股份变动月报。报告期为2026年2月，公司已发行股份数量和注册股本均未发生变化，整体股本规模维持不变。报告显示，截至2026年2月28日，公司注册股本合计为人民币2,670,429,325元。其中，H股法定股本551,940,500股，A股法定股本2,118,488,825股，均与上月底持平。期末公司H股已发行股份为540,971,500股，库存股份为10,969,000股；A股已发行股份为2,098,582,573股，库存股份为19,906,252股，均无新增发行或注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"gpt_icon":0},{"id":"2617518230","title":"复星医药03月04日遭主力抛售224.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617518230","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617518230?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:15","pubTimestamp":1772612149,"startTime":"0","endTime":"0","summary":"03月04日, 复星医药股价跌1.97%，报收18.45元，成交金额6286.5万元，换手率0.63%，振幅3.67%，量比1.30。复星医药今日主力资金净流出224.8万元，连续6日净流出，上一交易日主力净流出439.9万元。该股近5个交易日下跌9.08%，主力资金累计净流出1063.9万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2290.4万元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304161925a44a5d06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304161925a44a5d06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"2616583528","title":"索宝蛋白：股东济南复星、宁波复星合计减持538万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616583528","media":"雷达Finance","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616583528?lang=zh_cn&edition=full","pubTime":"2026-03-04 10:43","pubTimestamp":1772592187,"startTime":"0","endTime":"0","summary":"雷达财经 文|冯秀语 编|李亦辉3月3日，宁波索宝蛋白科技股份有限公司发布公告称，其股东济南财金复星惟实股权投资基金合伙企业及其一致行动人上海复星创富投资管理股份有限公司－宁波梅山保税港区复星惟盈股权投资基金合伙企业因自身经营发展需要，于2025年12月3日至2026年3月2日期间，减持了公司股份共计5,380,400股，占总股本的2.81%，减持价格区间为17.30至19.89元/股，减持总金额达96,778,143.50元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304104425a6a008cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304104425a6a008cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","BK1593","00656","02196"],"gpt_icon":0},{"id":"2616041473","title":"豫园股份控股股东复星高科技一致行动人新增质押2.45亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616041473","media":"中访网数据","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616041473?lang=zh_cn&edition=full","pubTime":"2026-03-04 03:40","pubTimestamp":1772566800,"startTime":"0","endTime":"0","summary":"控股股东复星高科技及其全部一致行动人合计持有公司股份24.10亿股，占总股本的61.91%，累计质押股份数量增至18.37亿股，占其合计持股的76.24%。公告显示，复星高科技及其一致行动人未来半年内到期的质押股份为1.77亿股，对应融资余额约4.31亿元；未来一年内到期的质押股份为2.91亿股，对应融资余额约6.86亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034029a69eb89f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034029a69eb89f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","00656","BK1230"],"gpt_icon":0},{"id":"2616358357","title":"华阳智能：复星惟盈减持133万股，占总股本的2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616358357","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616358357?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:59","pubTimestamp":1772539141,"startTime":"0","endTime":"0","summary":"3月3日，华阳智能（301502）发布公告，持股5%以上股东宁波梅山保税港区复星惟盈股权投资基金合伙企业在减持计划期限内累计减持股份133万股，占公司总股本的2.33%。2025年前三季度，华阳智能实现收入3.18亿元，归母净利润2460万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303195953a69d7c5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303195953a69d7c5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","02196","BK1515"],"gpt_icon":0},{"id":"2616126304","title":"易慕峰完成Pre-IPO轮融资，创始人孙敏敏曾任复星高管","url":"https://stock-news.laohu8.com/highlight/detail?id=2616126304","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616126304?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:55","pubTimestamp":1772538921,"startTime":"0","endTime":"0","summary":"瑞财经王敏3月3日，据华兴资本官微消息，深圳易慕峰生物科技股份有限公司完成近2亿元Pre-IPO轮融资。包括本轮在内，易慕峰在不到一年时间内完成三轮融资，累计融资总额超过6亿元人民币。易慕峰创始人为孙敏敏，曾任复星凯瑞总裁助理，参与中国首款CAR-T药物阿基仑赛的引进，具有细胞治疗产业化经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303200537a69d8209&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303200537a69d8209&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","00656","BK1230"],"gpt_icon":0},{"id":"2616634583","title":"每日卖空追踪 | 复星医药 03月03日卖空量成交7.35万股，卖空比例为2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616634583","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616634583?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:30","pubTimestamp":1772526629,"startTime":"0","endTime":"0","summary":"复星医药北京时间03月03日，跌2.69%，卖空量成交7.35万股，较上一交易日减少84.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163352a69cab86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163352a69cab86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2616583571","title":"复星医药03月03日遭主力抛售439.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616583571","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616583571?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:15","pubTimestamp":1772525738,"startTime":"0","endTime":"0","summary":"03月03日, 复星医药股价跌2.69%，报收18.82元，成交金额6031.4万元，换手率0.59%，振幅4.86%，量比1.26。复星医药今日主力资金净流出439.9万元，连续5日净流出，上一交易日主力净流出31.8万元。该股近5个交易日下跌7.36%，主力资金累计净流出1134.0万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2080.8万元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303161805a445b809&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303161805a445b809&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2616538865","title":"【券商聚焦】招银国际：AI将改变创新药物研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2616538865","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616538865?lang=zh_cn&edition=full","pubTime":"2026-03-02 14:40","pubTimestamp":1772433633,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2026年初至今累计上涨5.0%，跑赢MSCI中国指数6.2%。医药行业近期明显回调（MSCI中国医疗指数1月15日至今累计下跌9%），特别是创新药板块回调幅度较大（恒生生物科技指数1月15日至今累计下跌13%）。该机构认为，此轮调整原因包括博弈层面行业短期缺乏催化剂，以及行业轮动导致资金流出医药板块。中国创新药资产出海BD持续超预期，MNC对于中国资产的购买范围从单个管线拓宽至平台合作，进一步体现了中国创新药的竞争力。该机构认为，中国的AI制药技术发展迅猛，将涌现一批优秀的创新企业。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","LU0640798160.USD","LU2476274720.SGD","LU0588546209.SGD","BK1197","SG9999004311.SGD","LU0348783233.USD","LU0634319403.HKD","LU2328871848.SGD","SG9999014674.SGD","09688","01789","06160","159992","LU1969619763.USD","LU0348827113.USD","LU1720050803.USD","LU0348825331.USD","06978","BK1574","02228","09926","BK1583","LU1303224171.USD","BK1100","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","LU0348784397.USD","IE00B543WZ88.USD","BK1161","BK1585","02196","LU2399975544.HKD","LU0307460666.USD","01099","01530","BK1515","LU1961090484.USD","LU1251922891.USD","LU0561508036.HKD","HK0000165453.HKD","02268","BK1617","LU1115378108.SGD","02367","IE00BPRC5H50.USD","BK1141","LU0348735423.USD","BK1207"],"gpt_icon":0},{"id":"2616800646","title":"复星医药加快创新成果转化，2个1类创新药获批，7个重磅新药正在冲刺","url":"https://stock-news.laohu8.com/highlight/detail?id=2616800646","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616800646?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:14","pubTimestamp":1772417640,"startTime":"0","endTime":"0","summary":"复星医药作为国内创新型国际化医药企业，坚持创新驱动，加快创新成果转化。此外，复星医药还有7款新药冲刺，其中盐酸莫托咪酯注射液药品注册申请已获受理，拟用于麻醉诱导等；丁二酸复瑞替尼胶囊上市申请获受理，用于治疗ALK阳性非小细胞肺癌等；HLX22单抗注射液用于治疗胃癌的III期临床正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302102224a72f726c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302102224a72f726c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1593","BK1191","02196","06978","BK1515"],"gpt_icon":0},{"id":"2616450978","title":"每周股票复盘：复星医药（600196）分拆复星安特金赴港上市获股东会通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2616450978","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616450978?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:17","pubTimestamp":1772306229,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，复星医药报收于26.48元，较上周的26.57元下跌0.34%。本周关注点公司公告汇总：复星医药分拆复星安特金至港交所主板上市相关议案获临时股东会及H股类别股东会通过。出席会议A股股东代表有表决权股份占A股总数46.05%，H股股东占H股总数26.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0060","BK0012","BK1593","BK1191","BK1515","BK0239","BK0096","02196","BK0175","BK0188","BK0183","600196","BK0187"],"gpt_icon":0},{"id":"2614850107","title":"复星医药：2026年第一次A股类别股东会审议不通过分拆所属子公司复星安特金至香港联交所主板上市仅向H","url":"https://stock-news.laohu8.com/highlight/detail?id=2614850107","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614850107?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:30","pubTimestamp":1772195418,"startTime":"0","endTime":"0","summary":"复星医药 公告，2026年第一次临时股东会、A股类别股东会及H股类别股东会于2026年2月27日召开。临时股东会审议通过关于分拆所属子公司复星安特金至香港联交所主板上市相关议案，包括符合法律法规规定、上市方案、预案等11项议案；2026年第一次A股类别股东会未通过关于仅向H股股东提供保证配额的议案，该议案未获出席中小股东三分之二以上表决权通过；2026年第一次H股类别股东会通过了相同议案。出席会议的股东所持表决权股份总数为111029.463万股，占公司有表决权股份总数的42.0637%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227204136a437662f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227204136a437662f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1191","00656","02196","BK1230"],"gpt_icon":0},{"id":"2614009267","title":"【券商聚焦】交银国际：2026年医药板块稳中向好态势或将延续 但仍有短期波动可能","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009267","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614009267?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:45","pubTimestamp":1772156713,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，本周2026ASCOGU大会常规摘要公布，此次大会将于本月2628号召开，共有超过70项我国专家主导的研究入选，荣昌、翰森、科伦博泰、映恩生物等中国创新药企将携重磅数据亮相，临床数据密集释放有望阶段性催化板块行情。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975588","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","BK1207","BK1617","03329","06160","09688","IE00B543WZ88.USD","02268","BK1100","01099","LU0634319403.HKD","LU1720050803.USD","LU1961090484.USD","BK1191","02196","09926","LU0348825331.USD","02367","09939","LU0348767384.USD","LU2476274720.SGD","BK1588","HK0000165453.HKD","LU2778985437.USD","LU2476274308.USD","LU2488822045.USD","LU0417516738.SGD","SG9999014674.SGD","LU0348827113.USD","BK1141","LU1251922891.USD","LU0588546209.SGD","BK1197","LU0640798160.USD","03933","IE00BPRC5H50.USD","159938","LU0540923850.HKD","01530","LU0417516902.SGD","02228","LU0348784397.USD","LU1770034418.SGD","LU0417516571.SGD","LU1794554557.SGD","BK1147","BK1515","01789","BK1161","LU2399975544.HKD"],"gpt_icon":0},{"id":"2614012162","title":"复星医药(02196)向专业投资者公开发行公司债券获中国证监会注册批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614012162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614012162?lang=zh_cn&edition=full","pubTime":"2026-02-26 18:37","pubTimestamp":1772102236,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，近日，本公司收到中国证券监督管理委员会(中国证监会)出具的《关于同意上海复星医药(集团)股份有限公司向专业投资者公开发行科技创新公司债券注册的批复》(证监许可[2026]298号)(批复)。根据批复，中国证监会同意本公司向专业投资者公开发行面值总额不超过人民币60亿元科技创新公司债券的注册申请。该批复自同意注册之日起24个月内有效，本公司在注册有效期内可分期发行科技创新公司债券。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0096","02196","BK0028","BK0188","BK0187","BK1515","BK0183","BK1593","BK1191","BK0060","BK0175","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2614162390","title":"复星医药（600196）披露召开临时股东大会审议分拆复星安特金赴港上市议案，2月26日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614162390","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614162390?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:18","pubTimestamp":1772097521,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，复星医药报收于26.51元，较前一交易日上涨0.11%，最新总市值为707.93亿元。近日，复星医药发布《关于召开2026年第一次临时股东会、2026年第一次A股类别股东会及2026年第一次H股类别股东会的提示性公告》。A股股东可通过现场或网络投票方式参与，股权登记日为2026年2月24日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600026173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1191","BK0183","BK0060","BK0175","BK1515","BK1593","BK0028","BK0096","600196","BK0239","BK0187","02196","BK0188","BK0012"],"gpt_icon":0},{"id":"2614276450","title":"索宝蛋白：济南复星、宁波复星合计减持262.44万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2614276450","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614276450?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:57","pubTimestamp":1772096276,"startTime":"0","endTime":"0","summary":"格隆汇2月26日丨索宝蛋白(603231.SH)公布，于2025年12月8日-2026年2月25日期间，济南复星、宁波复星通过集中竞价和大宗交易方式合计减持公司股份262.44万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226165804a721b449&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226165804a721b449&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00656","BK1593","BK1515","BK1191","02196"],"gpt_icon":0},{"id":"2614027690","title":"每日卖空追踪 | 复星医药 02月26日卖空量成交2.65万股，卖空比例为0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614027690","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614027690?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:30","pubTimestamp":1772094628,"startTime":"0","endTime":"0","summary":"复星医药北京时间02月26日，跌3.27%，卖空量成交2.65万股，较上一交易日减少32.91%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163358a4cab528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163358a4cab528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0495},{"period":"1month","weight":-0.0604},{"period":"3month","weight":-0.1234},{"period":"6month","weight":-0.2206},{"period":"1year","weight":0.268},{"period":"ytd","weight":-0.0368}],"compareEarnings":[{"period":"1week","weight":-0.0402},{"period":"1month","weight":-0.0564},{"period":"3month","weight":-0.0293},{"period":"6month","weight":-0.0038},{"period":"1year","weight":0.0732},{"period":"ytd","weight":-0.0121}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.040726},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}